Compare Stocks: PHIO, CELU, HOWL, and TVGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.55 -1.9%	$1.17	$0.56 ▼ $2.55	$44.87M	0.77	1.40 million shs	26,350 shs
HOWL Werewolf Therapeutics	$0.92 +0.1%	$0.76	$0.27 ▼ $2.13	$44.81M	0.51	2.63 million shs	174,415 shs
PHIO Phio Pharmaceuticals	$0.99 -0.8%	$1.06	$0.81 ▼ $4.19	$11.46M	0.84	1.47 million shs	57,639 shs
TVGN Tevogen Bio	$6.86 +5.7%	$6.99	$3.64 ▼ $39.00	$44.65M	0.19	8,517 shs	2,838 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	-7.60%	+15.33%	-5.95%	+116.59%	-24.04%
HOWL Werewolf Therapeutics	-0.86%	+1.32%	-4.58%	+156.25%	-54.58%
PHIO Phio Pharmaceuticals	+0.34%	-3.46%	-7.93%	-7.93%	-57.86%
TVGN Tevogen Bio	-1.67%	-3.85%	-11.58%	+24.81%	-79.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.55 -1.9%	$1.17	$0.56 ▼ $2.55	$44.87M	0.77	1.40 million shs	26,350 shs
HOWL Werewolf Therapeutics	$0.92 +0.1%	$0.76	$0.27 ▼ $2.13	$44.81M	0.51	2.63 million shs	174,415 shs
PHIO Phio Pharmaceuticals	$0.99 -0.8%	$1.06	$0.81 ▼ $4.19	$11.46M	0.84	1.47 million shs	57,639 shs
TVGN Tevogen Bio	$6.86 +5.7%	$6.99	$3.64 ▼ $39.00	$44.65M	0.19	8,517 shs	2,838 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	-7.60%	+15.33%	-5.95%	+116.59%	-24.04%
HOWL Werewolf Therapeutics	-0.86%	+1.32%	-4.58%	+156.25%	-54.58%
PHIO Phio Pharmaceuticals	+0.34%	-3.46%	-7.93%	-7.93%	-57.86%
TVGN Tevogen Bio	-1.67%	-3.85%	-11.58%	+24.81%	-79.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	1.00	Sell	N/A	N/A
HOWL Werewolf Therapeutics	2.43	Hold	$4.00	334.31% Upside
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,319.88% Upside
TVGN Tevogen Bio	1.50	Reduce	$100.00	1,357.73% Upside

Current Analyst Ratings Breakdown

Latest PHIO, CELU, HOWL, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/5/2026	HOWL Werewolf Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/10/2026	HOWL Werewolf Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	TVGN Tevogen Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.69	N/A	N/A	($1.32) per share	-1.17
HOWL Werewolf Therapeutics	$1.88M	23.81	N/A	N/A	$0.51 per share	1.81
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($211.84) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$2.73	N/A	N/A	N/A	-374.87%	N/A	-64.45%	11/13/2026 (Estimated)
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-87.41%	-79.76%	11/12/2026 (Estimated)
TVGN Tevogen Bio	-$26.27M	-$4.63	N/A	N/A	N/A	N/A	N/A	-468.32%	11/13/2026 (Estimated)

Latest PHIO, CELU, HOWL, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	HOWL Werewolf Therapeutics	-$0.22	N/A	N/A	N/A	$18.31 million	N/A
9/29/2026	Q1 2026	CELU Celularity	N/A	$0.02	N/A	$0.02	N/A	$3.85 million
8/14/2026	Q2 2026	TVGN Tevogen Bio	-$2.53	-$1.52	+$1.01	-$1.52	N/A	N/A
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.09	0.08
HOWL Werewolf Therapeutics	N/A	2.91	2.91
PHIO Phio Pharmaceuticals	N/A	8.39	8.39
TVGN Tevogen Bio	N/A	0.33	0.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
HOWL Werewolf Therapeutics	64.84%
PHIO Phio Pharmaceuticals	57.31%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
HOWL Werewolf Therapeutics	23.60%
PHIO Phio Pharmaceuticals	3.52%
TVGN Tevogen Bio	65.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	115	28.95 million	23.94 million	Optionable
HOWL Werewolf Therapeutics	14	48.60 million	37.13 million	Optionable
PHIO Phio Pharmaceuticals	6	11.62 million	11.21 million	Not Optionable
TVGN Tevogen Bio	18	6.51 million	2.24 million	N/A

PHIO, CELU, HOWL, and TVGN Headlines

Recent News About These Companies

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

September 30, 2026 | globenewswire.com

Tevogen Bio Holdings Rebrands as Tevogen Inc.

July 30, 2026 | tipranks.com

Tevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGN

July 24, 2026 | benzinga.com

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

July 13, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative

June 10, 2026 | finanznachrichten.de

Tevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO Acquisitions

June 9, 2026 | quiverquant.comQ

Tevogen Announces Formation of a Healthcare Services Initiative

June 9, 2026 | globenewswire.com

Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | finanznachrichten.de

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...

May 28, 2026 | enidnews.comE

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 28, 2026 | globenewswire.com

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...

May 21, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare Transaction

May 21, 2026 | quiverquant.comQ

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

May 21, 2026 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth Initiatives

May 18, 2026 | quiverquant.comQ

Letter to Shareholders from CEO Dr. Ryan Saadi

May 18, 2026 | globenewswire.com

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...

May 12, 2026 | caledonianrecord.comC

Tevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLP

May 12, 2026 | quiverquant.comQ

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

May 12, 2026 | globenewswire.com

Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training Commercialization

May 5, 2026 | finance.yahoo.com

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

April 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, CELU, HOWL, and TVGN Company Descriptions

Celularity NASDAQ:CELU

$1.55 -0.03 (-1.90%)

As of 12:14 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Werewolf Therapeutics NASDAQ:HOWL

$0.92 +0.00 (+0.09%)

As of 12:25 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Phio Pharmaceuticals NASDAQ:PHIO

$0.99 -0.01 (-0.84%)

As of 12:20 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Tevogen Bio NASDAQ:TVGN

$6.86 +0.37 (+5.70%)

As of 12:25 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, CELU, HOWL, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, CELU, HOWL, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, CELU, HOWL, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, CELU, HOWL, and TVGN Company Descriptions

Celularity NASDAQ:CELU

Werewolf Therapeutics NASDAQ:HOWL

Phio Pharmaceuticals NASDAQ:PHIO

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHIO, CELU, HOWL, and TVGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHIO, CELU, HOWL, and TVGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHIO, CELU, HOWL, and TVGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO, CELU, HOWL, and TVGN Company Descriptions

Celularity NASDAQ:CELU

Werewolf Therapeutics NASDAQ:HOWL

Phio Pharmaceuticals NASDAQ:PHIO

Tevogen Bio NASDAQ:TVGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools